MiMedx Group, Inc (NASDAQ:MDXG - Get Free Report) has been given an average rating of "Moderate Buy" by the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.50.
A number of equities research analysts have commented on MDXG shares. Citizens Jmp cut their target price on shares of MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating for the company in a research report on Thursday, April 30th. Weiss Ratings reissued a "sell (d)" rating on shares of MiMedx Group in a report on Thursday. Finally, Wall Street Zen downgraded MiMedx Group from a "hold" rating to a "sell" rating in a research note on Saturday, August 1st.
View Our Latest Research Report on MDXG
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of MiMedx Group in the 2nd quarter worth $46,795,000. Paradigm Capital Management Inc. NY purchased a new position in MiMedx Group during the second quarter valued at $15,681,000. Nantahala Capital Management LLC bought a new stake in MiMedx Group during the third quarter valued at about $10,237,000. Marshall Wace LLP increased its position in MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock worth $9,351,000 after buying an additional 1,238,132 shares in the last quarter. Finally, Hillsdale Investment Management Inc. purchased a new stake in MiMedx Group in the fourth quarter worth about $7,134,000. Hedge funds and other institutional investors own 79.15% of the company's stock.
MiMedx Group Stock Performance
NASDAQ MDXG opened at $4.27 on Monday. MiMedx Group has a 12 month low of $3.03 and a 12 month high of $7.97. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The stock's fifty day moving average price is $4.04 and its 200-day moving average price is $4.14. The stock has a market cap of $622.40 million, a P/E ratio of 106.78 and a beta of 1.45.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. As a group, equities analysts forecast that MiMedx Group will post -0.1 EPS for the current fiscal year.
About MiMedx Group
(
Get Free Report)
MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.
MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
